...
首页> 外文期刊>Seminars in perinatology >CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations
【24h】

CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations

机译:CRISPR / CAS9基因编辑:研究技术,临床应用和道德考虑因素

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Gene therapy carries the potential to treat more than 10,000 human monogenic diseases and benefit an even greater number of complex polygenic conditions. The repurposing of CRISPR/Cas9, an ancient bacterial immune defense system, into a gene-editing technology has armed researchers with a revolutionary tool for gene therapy. However, as the breadth of research and clinical applications of this technology continues to expand, outstanding technical challenges and ethical considerations will need to be addressed before clinical applications become commonplace. Here, we review CRISPR/Cas9 technology and discuss its benefits and limitations in research and the clinical context, as well as ethical considerations surrounding the use of CRISPR gene editing.
机译:基因疗法携带潜力来治疗超过10,000个人的单一疾病,有利于甚至更大的复杂多种子条件。 古老的细菌免疫防御系统,进入基因编辑技术的CRISPR / CAS9的重新促使具有武装研究人员,具有革命性的基因治疗工具。 然而,由于这种技术的研究和临床应用的广度继续扩大,因此在临床应用普遍存在之前需要解决优异的技术挑战和道德考虑。 在这里,我们审查CRISPR / CAS9技术,并讨论其在研究和临床环境中的利益和局限,以及围绕使用CRISPR基因编辑的道德考虑。

著录项

  • 来源
    《Seminars in perinatology》 |2018年第8期|共14页
  • 作者单位

    Department of Cell and Developmental Biology University College London;

    Yale Cardiovascular Research Center Section of Cardiovascular Medicine Yale School of Medicine;

    Yale Cardiovascular Research Center Section of Cardiovascular Medicine Yale School of Medicine;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 产科学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号